RadNet Inc. (RADN) has acquired Gleamer, a clinical artificial intelligence firm, to expand its diagnostic imaging capabilities. The move aims to improve workflow efficiency and strengthen its competitive edge in the healthcare technology sector.
- RadNet (RADN) acquired Gleamer to enhance clinical AI capabilities in diagnostic imaging
- Target: 25% improvement in radiology workflow efficiency by 2027
- Integration into 450+ imaging centers across RadNet’s network
- Annual processing of 12 million imaging studies with AI-assisted analysis
- Acquisition led to 7.3% after-hours stock rise for RADN
- Deployment expected across 150 centers by mid-2026
RadNet Inc. (RADN) has finalized the acquisition of Gleamer, a specialized artificial intelligence developer focused on clinical imaging solutions, to advance its diagnostic platform. The acquisition integrates Gleamer’s deep learning algorithms into RadNet’s existing infrastructure, targeting a 25% improvement in radiology workflow efficiency by 2027. Gleamer’s technology enables automated image analysis for early detection of abnormalities in mammography, CT, and MRI scans, reducing interpretation time and minimizing human error. The transaction marks a strategic expansion of RadNet’s digital health portfolio, positioning the company at the forefront of AI-driven diagnostics. With the integration of Gleamer’s tools across RadNet’s network of 450+ imaging centers, the company expects to process 12 million imaging studies annually with enhanced accuracy. This capability supports faster patient diagnoses and improved care continuity, especially in high-volume regions. The acquisition comes amid rising investor interest in health tech firms with scalable AI applications. Shares of RadNet (RADN) rose 7.3% in after-hours trading following the announcement, while peers Vertex Pharmaceuticals (VRTX) and Intuitive Surgical (ISRG) saw modest gains, reflecting broader market enthusiasm for AI-augmented healthcare solutions. Analysts suggest that strengthened AI capabilities could drive long-term revenue growth and margin expansion for RadNet. The integration is expected to be completed by mid-2026, with initial deployment in 150 high-traffic imaging centers. Clinical validation studies are underway to assess real-world impact on diagnostic precision and throughput. The move underscores the growing reliance on AI to address workforce shortages and rising imaging demand in the U.S. healthcare system.